peripheral blood mesenchymal stem cells

Cell therapyexperimental

Clinical trial activity

7 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2013 (NCT03239535)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Stem CellSupplementation

    Stem Cell supplementation

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • pbmcs
  • peripheral blood mesenchymal stem cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04953572Phase 1Aug 1, 2021Hebei University, Inner Mongolia International Mongolian Hospital, Peking University, Tianjin University
NCT03976206Phase 1/Phase 2 (Phase 2)Jul 31, 2019Guangzhou Four-Leaf Clover HealthTech Co., Ltd., Jinan University
NCT03985462Phase 1/Phase 2 (Phase 2)Jun 30, 2019Guangzhou Four-Leaf Clover HealthTech Co., Ltd., Jinan University
NCT03975101Phase 1/Phase 2 (Phase 2)Jun 15, 2019Guangzhou Four-Leaf Clover HealthTech Co., Ltd., Jinan University
NCT03044119Phase 1Mar 20, 2017KLE Society's Institute of Dental Sciences
NCT02977052Phase 2Nov 1, 2016Bristol-Myers Squibb, Netherlands Cancer Institute
NCT03239535Phase 1/Phase 2 (Phase 2)Oct 1, 2013Government of Russia
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Guangzhou Four-Leaf Clover HealthTech Co., Ltd.Government3012019
Jinan UniversityAcademic/Hospital3312019
Bristol-Myers SquibbFor profit1012016
Government of RussiaGovernment1112013
Hebei UniversityAcademic/Hospital1012021
Inner Mongolia International Mongolian HospitalAcademic/Hospital1012021
KLE Society's Institute of Dental SciencesAcademic/Hospital1112017
Netherlands Cancer InstituteAcademic/Hospital1112016
Peking UniversityAcademic/Hospital1112021
Tianjin UniversityAcademic/Hospital1012021
10 organizations
Page 1 / 1